Park Avenue Securities LLC Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Park Avenue Securities LLC increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 39.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,701 shares of the company’s stock after acquiring an additional 760 shares during the period. Park Avenue Securities LLC’s holdings in Medpace were worth $897,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. State Street Corp increased its stake in Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company’s stock worth $251,337,000 after purchasing an additional 50,312 shares during the period. Geode Capital Management LLC boosted its position in Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after purchasing an additional 44,371 shares in the last quarter. Wellington Management Group LLP increased its position in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after buying an additional 109,886 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of Medpace by 55.1% in the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after buying an additional 143,481 shares during the last quarter. Finally, American Capital Management Inc. boosted its position in Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock valued at $127,060,000 after buying an additional 9,592 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 3.0 %

MEDP stock opened at $347.52 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $286.76 and a 12-month high of $459.77. The business’s 50-day moving average is $340.00 and its 200 day moving average is $356.52. The stock has a market cap of $10.80 billion, a price-to-earnings ratio of 30.43, a PEG ratio of 1.73 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. During the same period in the previous year, the company posted $2.22 earnings per share. The business’s revenue was up 8.3% on a year-over-year basis. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. UBS Group cut Medpace from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $420.00 to $350.00 in a report on Friday, September 27th. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Redburn Atlantic started coverage on shares of Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 target price on the stock. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and cut their price target for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Finally, TD Cowen lowered their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average price target of $380.56.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.